NeoPharm (NEOL) Posts Q3 Loss of $0.06
More News related to NEOL
- NeoPharm Presents the Phase II Data of Liposome-Entrapped Paclitaxel (LEP) in Patients with Metastatic Breast Cancer
- NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
- NeoPharm (NEOL) Posts Q3 Loss of $0.06
- NeoPharm (NEOL) Requests Hearing for Continued Listing on NASDAQ
- NeoPharm (NEOL) Begins Enrollment for Phase II Trial of Liposomal Paclitaxel
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
NeoPharm, Inc. (NASDAQ: NEOL) reports Q3 loss of $0.06, compared to ($0.08) in the same quarter last year.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
